Have a feature idea you'd love to see implemented?
Let us know!
AXSM Axsome Therapeutics Inc
Price (delayed)
$84.6
Market cap
$4.1B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.58
Enterprise value
$3.96B
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people
Highlights
AXSM's gross profit has surged by 52% year-on-year and by 17% since the previous quarter
The revenue has soared by 51% YoY and by 16% from the previous quarter
The equity has dropped by 66% year-on-year and by 10% since the previous quarter
The net income has plunged by 54% YoY
Key stats
What are the main financial stats of AXSM
Market
Valuations
Earnings
Shares outstanding
48.46M
Market cap
$4.1B
Enterprise value
$3.96B
Price to earnings (P/E)
N/A
Price to book (P/B)
43.71
Price to sales (P/S)
12.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.71
Revenue
$338.46M
Gross profit
$308.29M
Net income
-$310.96M
EBIT
-$306.22M
EBITDA
-$297.22M
Free cash flow
-$132.82M
Per share
Balance sheet
Liquidity
EPS
-$6.58
EPS diluted
-$6.58
Free cash flow per share
-$2.76
Book value per share
$1.94
Revenue per share
$7.03
TBVPS
$10.41
Total assets
$561.46M
Total liabilities
$468.56M
Debt
$191.02M
Equity
$92.9M
Working capital
$282.93M
Debt to equity
2.06
Current ratio
2.44
Quick ratio
2.3
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
-87.8%
Gross margin
91.1%
Net margin
-91.9%
Operating margin
-90.5%
Return on assets
-55.4%
Return on equity
-234.3%
Return on invested capital
-169.6%
Return on capital employed
-83.8%
Return on sales
-90.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AXSM stock price
How has the Axsome Therapeutics stock price performed over time
Intraday
-5.23%
1 week
0.98%
1 month
-6.1%
1 year
-0.72%
YTD
-0.01%
QTD
-0.01%
Financial performance
How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$338.46M
Gross profit
$308.29M
Operating income
-$306.22M
Net income
-$310.96M
Gross margin
91.1%
Net margin
-91.9%
The company's operating income has shrunk by 58% YoY
The net income has plunged by 54% YoY
AXSM's gross profit has surged by 52% year-on-year and by 17% since the previous quarter
The revenue has soared by 51% YoY and by 16% from the previous quarter
Growth
What is Axsome Therapeutics's growth rate over time
Valuation
What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
43.71
P/S
12.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.71
The EPS has contracted by 45% YoY
The equity has dropped by 66% year-on-year and by 10% since the previous quarter
The P/B is 35% higher than the last 4 quarters average of 32.4 and 21% higher than the 5-year quarterly average of 36.0
The revenue has soared by 51% YoY and by 16% from the previous quarter
The price to sales (P/S) is 12% lower than the last 4 quarters average of 13.6
Efficiency
How efficient is Axsome Therapeutics business performance
The ROE has plunged by 123% YoY and by 34% from the previous quarter
AXSM's ROA is down by 33% YoY and by 2.4% QoQ
The company's return on invested capital fell by 19% YoY and by 3% QoQ
The ROS has grown by 14% from the previous quarter but it has contracted by 4.5% YoY
Dividends
What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AXSM.
Financial health
How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 20% more than its total liabilities
The quick ratio has contracted by 47% YoY
AXSM's current ratio is down by 45% year-on-year
Axsome Therapeutics's debt is 106% higher than its equity
The debt to equity has soared by 199% YoY and by 11% QoQ
The equity has dropped by 66% year-on-year and by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.